Founded in Toulouse, France, Boydsense is dedicated to creating non-invasive and affordable tools for measuring critical biomarkers through exhaled breath. The company's core mission is to revolutionize health monitoring by providing accessible and user-friendly diagnostic solutions. Boydsense's innovative technology aims to offer a painless alternative to traditional blood tests, making it easier for individuals to manage their health. Their primary market focus includes patients with chronic conditions such as diabetes, where continuous monitoring is crucial.

Boydsense has garnered attention from notable investors and industry experts who recognize the potential of their groundbreaking technology. The leadership team comprises experienced professionals in biotechnology and healthcare innovation. Key achievements include successful prototype development and initial clinical trials demonstrating the efficacy of their breath analysis technology. Boydsense's impact lies in its potential to transform health diagnostics, offering a more convenient and less invasive option for millions of patients worldwide.